BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 25776192)

  • 41. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
    Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu YZ; Devine SM; Klisovic R; Blum W; Marcucci G
    Leuk Lymphoma; 2016 Sep; 57(9):2100-8. PubMed ID: 26784138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
    Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
    Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
    Garitano-Trojaola A; Sancho A; Götz R; Eiring P; Walz S; Jetani H; Gil-Pulido J; Da Via MC; Teufel E; Rhodes N; Haertle L; Arellano-Viera E; Tibes R; Rosenwald A; Rasche L; Hudecek M; Sauer M; Groll J; Einsele H; Kraus S; Kortüm MK
    Commun Biol; 2021 Jun; 4(1):799. PubMed ID: 34172833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
    Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Andrews C; Maze D; Murphy T; Sibai H
    Br J Haematol; 2020 Aug; 190(3):467-470. PubMed ID: 32567045
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment practice and outcomes in
    Chua CC; Grigg A; Singh J; Droogleever MP; Zhang L; Lim A; Fong CY; Ting SB; Schwarer A; Tiong IS; Wei AH
    Leuk Lymphoma; 2020 Apr; 61(4):848-854. PubMed ID: 31752581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
    Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series.
    Tremblay Z; Wong A; Otis AS; Pépin MA; Bambace N; Soulières D; Bouchard P; Adam JP
    Eur J Haematol; 2022 Feb; 108(2):163-165. PubMed ID: 34653270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
    Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
    Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
    Sanz M; Burnett A; Lo-Coco F; Löwenberg B
    Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 57. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
    Voso MT; Larson RA; Jones D; Marcucci G; Prior T; Krauter J; Heuser M; Lavorgna S; Nomdedeu J; Geyer SM; Walker A; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte TM; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Amadori S; Cheng Y; Chen Y; Pallaud C; Du L; Piciocchi A; Ehninger G; Byrd J; Thiede C; Döhner K; Stone RM; Döhner H; Bloomfield CD; Lo-Coco F
    Blood Adv; 2020 Oct; 4(19):4945-4954. PubMed ID: 33049054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
    Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
    Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
    Rautenberg C; Nachtkamp K; Dienst A; Schmidt PV; Heyn C; Kondakci M; Germing U; Haas R; Kobbe G; Schroeder T
    Eur J Haematol; 2017 Apr; 98(4):348-354. PubMed ID: 27893163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.